The Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222), in Moderate-to-Severe Chronic Plaque Psoriasis Primary Efficacy Objective: To assess the efficacy of tildrakizumab (SCH-900222/MK-3222) (hereafter referred to as MK-3222) compared to placebo in the treatment of moderate-to-severe chronic plaque ps...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An Imaging Sub-Study of the Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium In postmenopausal women with osteoporosis: To estimate the effect of treatment with MK-0822 50 mg once weekly (OW) on volumetric trabecular bone mineral density (vBMD) at the lumbar spine (assessed ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Randomized, Double-Blind, Placebo-Controlled, Multicenter 16 Week Study to Assess the Effect of Vitamin D3 8400 IU Once Weekly on Body Sway and Neuromuscular Function in Men and Women Over 70 Years Old To compare change in mediolateral body sway (measured with eyes open using the AccuSwayPLUS platform) following administration of vitamin D3 8400 IU once-weekly for 16 weeks to that following administ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Comparison of Pediatric Formulation (liquid) to Adult Formulation (tablets) To evaluate the comparative bioavailability between: • MK-5348 (vorapaxar) 0.2085 mg/mL oral suspension from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., USA; and • MK-5348 (Zontiv...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Vaginal ring dysmenorrhea feasibility trial To identify at least one dose of progestin/estrogen amongst the 4 active doses being tested, administered as a vaginal ring, that shows clinically relevant treatment efficacy in relief of primary dysm...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Fosaprepitant PK/PD CINV in Pediatric Cancer Patients To determine the appropriate dosing regimen of fosaprepitant for the prevention of CINV in pediatric patients birth to 17 years of age, by assessing the pharmacokinetic and pharmacodynamic parameters,...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A clinical study in patients with complicated intra-abdominal infections (infections situated within the cavity of the abdomen) conducted to assess safety, tolerability and efficacy of the study drug (MK-7655) administered together with Imipenem/Cilastatin (an antibiotic) in comparison with Imipenem/Cilastatin administered alone 1. To evaluate the efficacy of two doses of MK-7655 + imipenem/cilastatin (250 mg and 125 mg), as compared with imipenem/cilastatin alone, with respect to the clinical response assessment profile in t...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

“Ensayo de fase III, aleatorizado, controlado con un fármaco de comparación activo, con doble enmascaramiento, de doce semanas de duración, para comparar la eficacia y la seguridad de MK-2452 (0,0015%) sin conservantes y de maleato de timolol (0,5%) sin conservantes en pacientes con glaucoma de ángulo abierto e hipertensión ocular” "A Phase III, Randomized, Active Comparator-Controlled, Twelve-Week, Double-Masked Clinical Trial to Compare the Efficacy and Safety of Preservative-Free MK-2452 (0.0015%) and Preservative-Free Timolol Maleate (0.5%) in Patients with Open-Angle Glaucoma and Ocular Hypertension Evaluar la eficacia de MK-2452 sin conservantes (0,0015 %) en comparación con el maleato de timolol sin conservantes (0,5 %) en lo que se refiere a la variación de la PIO con respecto al valor basal d...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study to evaluate the safety and efficacy of the addition of a new drug (MK-3102) compared with placebo in patients with Type 2 Diabetes. Estudio para evaluar la seguridad y eficacia de la adición de un nuevo fármaco (MK-3102) comparado con placebo en pacientes con Diabetes Mellitus de tipo 2 (1) After 24 weeks, to assess the effect of treatment with MK-3102 compared with placebo on A1C. (2) To assess the safety and tolerability of MK-3102. (1) Al cabo de 24 semanas, evaluar el efe...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

PhII Trial of Pembrolizumab in Advanced Solid Tumors Ensayo clínico de Fase II con pembrolizumab en pacientes con tumores sólidos avanzados Objective 1: To evaluate the ORR to pembrolizumab, based on RECIST 1.1 as assessed by independent central radiologic review, in biomarker-unselected subjects with any one of multiple types of advance...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune